Tag Archives: NASDAQ:MLND

Oppenheimer Remains a Hold on Millendo Therapeutics (MLND)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Millendo Therapeutics (MLND – Research Report), with a price target of $2.00. The company’s shares closed last Wednesday at $1.96, close to its 52-week low of

Millendo Therapeutics (MLND) Gets a Hold Rating from Oppenheimer

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Millendo Therapeutics (MLND – Research Report), with a price target of $2.00. The company’s shares closed last Monday at $1.45. According to TipRanks.com, Olson ‘s ranking

Oppenheimer Maintains Their Buy Rating on Millendo Therapeutics (MLND)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Millendo Therapeutics (MLND – Research Report). The company’s shares closed last Monday at $6.10, close to its 52-week low of $4.56. According to TipRanks.com, Olson is

Millendo Therapeutics (MLND) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Millendo Therapeutics (MLND – Research Report) today and set a price target of $25.00. The company’s shares closed last Monday at $6.58, close to its 52-week low of $4.56. According to

Wedbush Keeps a Buy Rating on Millendo Therapeutics Inc (MLND)

Wedbush analyst Laura Chico reiterated a Buy rating on Millendo Therapeutics Inc (MLND – Research Report) yesterday and set a price target of $24. The company’s shares closed last Monday at $6.97, close to its 52-week low of $6.77. According